Evaluasi Rasionalitas Penggunaan Obat Neuroprotektif pada Pasien Stroke Iskemik di Rumah Sakit Stroke Nasional Bukittinggi

Abstract

Abstract Background: Ischemic stroke is caused by local thrombus formation or embolism that occurs in the cerebral arteries. This causes a lack of blood flow so that the oxygen needed by brain tissue is also reduced. The incidence of ischemic stroke reaches 87%, the highest number of all other stroke cases. Neuroprotective drugs are one of the therapies aimed at reducing nerve damage caused by ischemic strokes. Objective: This study aimed to determine the demographic characteristics of ischemic stroke patients, patterns of drug used and the rationality for neuroprotective medicines of ischemic stroke patients. Methods: This study was designed as observational in which the data were collected from from inpatient medical record data in 2019 as many as 280 patients retrospectively. The data obtained will be compared to predetermined treatment standards. Results: The results showed that the greatest number of ischemic stroke patients was male by 63.2% with an age range of 55 - 64 years by 39%. The highest percentage of the latest educational status is high school reaching 47.1%, followed by the most employment status, namely IRT, with 28.2%. The most widely used neuroprotective drug is citicoline at 53.2%, with intravenous administration routes reaches 51.8%. The evaluation of neuroprotective drugs' rationality in the hospital included 100% appropriate indication, 99.3% appropriate patient, 100% appropriate medication, 97.9% appropriate dose, and 99.3% appropriate drug administration. Conclusions: The incidence of irrational therapy was still found in 8 patients, spread over on appropriate patient, right dose, and right drug administration. Keywords: ischemic stroke, neuroprotective drug, rationality